Gahan Pandina

Gahan Pandina

UNVERIFIED PROFILE

Are you Gahan Pandina?   Register this Author

Register author
Gahan Pandina

Gahan Pandina

Publications by authors named "Gahan Pandina"

Are you Gahan Pandina?   Register this Author

53Publications

1085Reads

13Profile Views

The EU-AIMS Longitudinal European Autism Project (LEAP): design and methodologies to identify and validate stratification biomarkers for autism spectrum disorders.

Mol Autism 2017 23;8:24. Epub 2017 Jun 23.

Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Kapittelweg 29, 6525 EN Nijmegen, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13229-017-0146-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481887PMC
March 2018

Calibration and cross-validation of MCCB and CogState in schizophrenia.

Psychopharmacology (Berl) 2015 Nov 29;232(21-22):3873-82. Epub 2015 May 29.

Institute of Brain, Behaviour & Mental Health, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00213-015-3960-8DOI Listing
November 2015

Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia.

Eur Neuropsychopharmacol 2015 Aug 31;25(8):1178-89. Epub 2015 Mar 31.

Section on Schizophrenia, Imaging and Therapeutics, Institute of Psychiatry, Psychology and Neuroscience, King׳s College London, PO Box 053, 16 De Crespigny Park, London SE5 8AF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euroneuro.2015.03.009DOI Listing
August 2015

Impact of self-reported juvenile abuse on treatment outcome in patients with major depressive disorder.

J Affect Disord 2013 Oct 10;151(1):384-91. Epub 2013 Jul 10.

Janssen Research & Development, LLC, Raritan, NJ 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jad.2013.01.053DOI Listing
October 2013

Identification of clinically meaningful relationships among cognition, functionality, and symptoms in subjects with schizophrenia or schizoaffective disorder.

Schizophr Res 2013 Feb 28;143(2-3):312-8. Epub 2012 Dec 28.

Janssen Research & Development, LLC, Titusville, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.schres.2012.11.031DOI Listing
February 2013

An open-label, multicenter evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia.

Child Adolesc Psychiatry Ment Health 2012 Jun 7;6(1):23. Epub 2012 Jun 7.

Janssen Research and Development, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1753-2000-6-23DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489792PMC
June 2012

Adjunctive risperidone in the treatment of generalized anxiety disorder: a double-blind, prospective, placebo-controlled, randomized trial.

Psychopharmacol Bull 2007 ;40(3):41-57

Johnson and Johnson Pharmaceutical Research and Development, Titusville, NJ, USA.

View Article

Download full-text PDF

Source
March 2012

Gender and schizophrenia.

Psychopharmacol Bull 2007 ;40(4):178-90

Janssen Pharmaceutica, Inc., Titusville, NJ, USA.

View Article

Download full-text PDF

Source
March 2012

Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trials.

Psychopharmacol Bull 2008 ;41(3):68-90

Johnson & Johnson Pharmaceutical Research & Development, Titusville, NJ, USA.

View Article

Download full-text PDF

Source
March 2012

A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia.

Prog Neuropsychopharmacol Biol Psychiatry 2011 Jan 16;35(1):218-26. Epub 2010 Nov 16.

Johnson & Johnson Pharmaceutical Research & Development, LLC, Raritan, New Jersey 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pnpbp.2010.11.008DOI Listing
January 2011

Psychometric evaluation of a Patient-Rated Most Troubling Symptom Scale for Depression: findings from a secondary analysis of a clinical trial.

Int Clin Psychopharmacol 2010 Mar;25(2):51-9

Johnson and Johnson Pharmaceutical Research and Development, 1125 Trenton-Harbourton Road, Titusville, NJ 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/YIC.0b013e3283320667DOI Listing
March 2010

Cognitive effects of topiramate in migraine patients aged 12 through 17 years.

Pediatr Neurol 2010 Mar;42(3):187-95

Psychiatry, Johnson & Johnson Pharmaceutical Research & Development L.L.C, Titusville, New Jersey 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pediatrneurol.2009.10.001DOI Listing
March 2010

Paliperidone extended-release tablets in patients with recently diagnosed schizophrenia.

Early Interv Psychiatry 2010 Feb;4(1):64-78

Ortho-McNeil Janssen Scientific Affairs, LLC, Titusville New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1751-7893.2010.00165.xDOI Listing
February 2010

Cognitive function with long-term risperidone in children and adolescents with disruptive behavior disorder.

J Child Adolesc Psychopharmacol 2009 Dec;19(6):749-56

Johnson & Johnson Pharmaceutical Research & Development, Titusville, New Jersey 08560, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cap.2008.0159
Publisher Site
http://dx.doi.org/10.1089/cap.2008.0159DOI Listing
December 2009

Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.

Br J Psychiatry 2009 Feb;194(2):158-64

Johnson & Johnson Pharmaceutical Research & Development, Division of Janssen Pharmaceutica NV, Beerse, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1192/bjp.bp.107.046177DOI Listing
February 2009

Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study.

Ann Gen Psychiatry 2009 Feb 11;8. Epub 2009 Feb 11.

HECON Associates Inc,, 9833 Whetstone Drive, Montgomery Village, MD 20886, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1744-859X-8-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649125PMC
February 2009

Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.

J Child Adolesc Psychopharmacol 2008 Aug;18(4):337-45

Johnson & Johnson Pharmaceutical Research and Development, Titusville, New Jersey 08530, USA.

View Article

Download full-text PDF

Source
http://www.liebertpub.com/doi/10.1089/cap.2007.0098
Publisher Site
http://dx.doi.org/10.1089/cap.2007.0098DOI Listing
August 2008

Assessment of strategies for switching patients from olanzapine to risperidone: a randomized, open-label, rater-blinded study.

BMC Med 2008 Jun 30;6:17. Epub 2008 Jun 30.

Western Psychiatric Institute and Clinic, O'Hara Street, Pittsburgh, PA 15213-2593, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-6-17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2474645PMC
June 2008

Anterior cingulate volume in pediatric bipolar disorder and autism.

J Affect Disord 2008 Jan 13;105(1-3):93-9. Epub 2007 Jun 13.

Department of Psychiatry and Behavioral Sciences and The Medical Investigation of Neurodevelopmental Disorders Institute, University of California, Davis Medical Center, CA 95817, United States.

View Article

Download full-text PDF

Source
http://linkinghub.elsevier.com/retrieve/pii/S016503270700143
Publisher Site
http://dx.doi.org/10.1016/j.jad.2007.04.019DOI Listing
January 2008

Risperidone for treatment-refractory major depressive disorder: a randomized trial.

Ann Intern Med 2007 Nov;147(9):593-602

Ortho-McNeil Janssen Scientific Affairs, Titusville, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7326/0003-4819-147-9-200711060-00003DOI Listing
November 2007

Risperidone and cognitive function in children with disruptive behavior disorders.

Biol Psychiatry 2007 Aug 8;62(3):226-34. Epub 2007 Jan 8.

Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, New Jersey 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.biopsych.2006.09.036DOI Listing
August 2007

Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.

J Child Adolesc Psychopharmacol 2007 Jun;17(3):312-27

Ortho-McNeil Janssen Scientific Affairs, L.L.C., Titusville, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2006.17309DOI Listing
June 2007

Evaluating movement disorders in pediatric patients receiving risperidone: a comparison of spontaneous reports and research criteria for TD.

Child Adolesc Psychiatry Ment Health 2007 Jun 26;1(1). Epub 2007 Jun 26.

Ortho-McNeil Janssen Scientific Affairs, L.L.C., Titusville, NJ, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1753-2000-1-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1939834PMC
June 2007

Direct health care costs for children with pervasive developmental disorders: 1996-2002.

Adm Policy Ment Health 2007 May 2;34(3):213-20. Epub 2006 Nov 2.

Regional Outcomes Research, Ortho McNeil-Janssen Scientific Affairs, LLC, 740 Waterford Drive, Grayslake, IL 60030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10488-006-0098-3DOI Listing
May 2007

Management of psychiatric disorders in children and adolescents with atypical antipsychotics: a systematic review of published clinical trials.

Eur Child Adolesc Psychiatry 2007 Mar 30;16(2):104-20. Epub 2006 Oct 30.

Center for the Advancement of Children's Mental Health, Columbia University, New York State Psychiatric Institute, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00787-006-0580-1DOI Listing
March 2007

Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial.

J Autism Dev Disord 2007 Feb;37(2):367-73

Medical Affairs, Janssen Pharmaceutica, Inc., Titusville, NJ 08560, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10803-006-0234-7DOI Listing
February 2007

Risperidone in the management of disruptive behavior disorders.

J Child Adolesc Psychopharmacol 2006 Aug;16(4):379-92

Medical Affairs Division, Janssen Pharmaceutica Products, L.P., Titusville, New Jersey, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/cap.2006.16.379DOI Listing
August 2006

Risperidone for the treatment of affective symptoms in children with disruptive behavior disorder: a post hoc analysis of data from a 6-week, multicenter, randomized, double-blind, parallel-arm study.

Clin Ther 2006 May;28(5):794-800

Clinical and Research Program in Pediatric Psychopharmacology, Department of Psychiatry, Massachusetts General Hospital, Boston, 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0149-2918(06)00132-9DOI Listing
May 2006

Effects of behavioral therapy on weight loss in overweight and obese patients with schizophrenia or schizoaffective disorder.

J Clin Psychiatry 2005 Feb;66(2):205-12

Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4088/jcp.v66n0208DOI Listing
February 2005

No seizure exacerbation from risperidone in youth with comorbid epilepsy and psychiatric disorders: a case series.

J Child Adolesc Psychopharmacol 2004 ;14(2):295-310

Children's Hospital Boston, Fegan 8, 300 Longwood Avenue, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/1044546041649075DOI Listing
October 2004

A preliminary meta-analysis of the child behavior checklist in pediatric bipolar disorder.

Biol Psychiatry 2003 Jun;53(11):1021-7

Pediatric Psychopharmacology Unit, Child Psychiatry Service, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0006-3223(03)00234-8DOI Listing
June 2003